Abstract 5735: Druggable gene alterations in Japanese patients with rare malignancy

Abstract 5735: Druggable gene alterations in Japanese patients with rare malignancy

Background: In the absence of a current standard of care, precision oncology with next-generation sequencing provides an important therapeutic option for patients with rare malignancy. Here, we sought to establish the clinical relevancy of comprehensive genomic profiling (CGP) for patients with rare...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.5735-5735
Hauptverfasser: Ohmoto, Akihiro, Hayashi, Naomi, Fukada, Ippei, Yamazaki, Masumi, Yunokawa, Mayu, Kasuga, Akiyoshi, Shinozaki, Eiji, Ueki, Arisa, Tonooka, Akiko, Takeuchi, Kengo, Mori, Seiichi, Kiyotani, Kazuma, Takahashi, Shunji
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: In the absence of a current standard of care, precision oncology with next-generation sequencing provides an important therapeutic option for patients with rare malignancy. Here, we sought to establish the clinical relevancy of comprehensive genomic profiling (CGP) for patients with rare malignancy. Methods: We reviewed 341 patients who underwent CGP (FoundationOne CDx; OncoGuide NCC OncoPanel System)in our institution between 2019 and 2021. Cases were classified as common or rare malignancy based on the Rare Cancers in Europe (RARECARE) definition (incidence of
ISSN:1538-7445
1538-7445
DOI:10.1158/1538-7445.AM2022-5735